{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-153471","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.584541+00:00","generated_at":"2026-05-18T10:00:33.702921+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verrica amends Torii deal: $8M milestone accelerated, $10M on Japan approval, $40M trial funding","bullets":["Torii pays $8M milestone in July 2025 for starting global Phase 3 common warts trial of YCANTH.","Torii to pay $10M cash upon Japanese approval of YCANTH for molluscum, expected by end-2025.","Torii funds first $40M of trial costs (~90% of budget); Verrica repays via future royalties/transfer price.","First patient dosing in U.S. Phase 3 common warts trial expected Q4 2025.","OrbiMed waived going-concern qualification requirement under credit agreement for remainder of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-153471","json":"https://secwatch.observer/filing/0001193125-25-153471.json","markdown":"https://secwatch.observer/filing/0001193125-25-153471.md","text":"https://secwatch.observer/filing/0001193125-25-153471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525153471/0001193125-25-153471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525153471/d682251d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:00:33.702921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}